Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Review Of Reviews: Drug Review Profiles 2013

Jan 21 2014

Related Content

Randomization Required: Liver Signal Necessitated <em>Kadcyla</em> Trial With Control Arm

Apr 16 2013

Ado-Over: FDA Uses Prefix To Get Ahead Of Pull-Down Menu Problem

Apr 17 2013

Ariad Took Dismissive View Of CV Events In <em>Iclusig</em> Labeling Proposals

Dec 17 2013

FDA Looked To <em>Arava</em>’s Safety Experience In Gauging <em>Aubagio</em>’s Risks

Mar 19 2013

<em>Aubagio</em> Approval Reflects FDA’s Evolving View On Multiple Sclerosis Drugs

Mar 19 2013

<em>Eliquis</em> Approval Delayed By Fraud, Dispensing Errors In Pivotal Trial

Jun 18 2013

“Marginal” Mortality Benefit Belongs In <em>Eliquis</em>’ Label, But Not The Indication Statement, FDA Says

Jun 18 2013

<em>Breo</em> Inverts Traditional Path To COPD Indication For LABA Combinations

Jul 23 2013

The Magnitude Matters: GSK Approvals Show How To Use PFS After Other Drugs Show Survival

Nov 20 2013

<em>Fulyzaq</em> Review Shows FDA Adapting Smoothly To Adaptive Trial Design

May 22 2013

A Question Of Identity: Drug & Botanical Perspectives On Manufacturing Clash In <em>Fulyzaq</em> Review

May 22 2013

Additional Topics

Regulation BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window